• VIF Estd. on 20 Jan 2015 u/s 3 of Indian Trusts Act, 1882
  • ISO 9001:2008 Certified
  • Phone: 044-22531502 | Mobile: +91 9840556456
  • Email: contact@venusinfo.org

Award Winner - 2017

  • Born: June 30, 1969, Mwanza, Tanzania

  • Affiliation at the time of award: National University of Singapore, Singapore

  • The Award: Distinguished Scientist in Neuropharmacology - 2017 Award
    (Certificate, Bronze Medal and Memento) has been bestowed to Dr. Gavin Stewart Dawe for his contribution, research excellence and accomplishments in the area of Neuropharmacology.

  • The Research Meet 2017
Gavin Stewart Dawe - Facts
  • Dr Gavin Stewart Dawe’s laboratory investigates the neuropharmacology of drugs for age-related neuroscience and mental health disorders with systems neurobiology, behavioural neuroscience, electrophysiological and optogenetic approaches. Significant research contributions including discovering fetal microchimerism in maternal brains, advancing understanding of the signalling functions of the amyloid precursor protein (APP) intracellular domain (AICD), and elucidating functions of the nucleus incertus and the neuropeptide relaxin-3.
  • Recent research in his laboratory focuses on peptide pharmacology. He is developing novel pepditomimetics and stapled peptides as receptor agonists/antagonists and inhibitors of protein interactions. Current projects focus on developing (1) relaxin-3 and neuropeptide Y receptor ligands for treatment of obesity, metabolic syndrome, anxiety and depression; and (2) inhibitors of the binding of APP domains for Alzheimer’s disease and associated neurological disorders.
  • Discipline: Medical Science
  • Area of Research: Neuropharmacology / Neuroscience
  • Research/Constancy Projects: (Ongoing/Completed)
    • Title: Stapled relaxin-3 B- chain peptides as novel RXFP3 agonists and antagonists
    • Funding Agency: Ministry of Education AcRF Tier 1 (Singapore)
  • Current R&D Activities:Dr. Gavin Stewart Dawe's lab investigates peptide pharmacology for neurological and neuropsychiatric disorders. They develop pepditomimetics and stapled peptides as receptor agonists/antagonists and inhibitors of protein interactions. Current projects focus on (1) relaxin-3 and neuropeptide Y for obesity, metabolic syndrome, anxiety and depression; and (2) inhibitors amyloid precursor protein (APP) domain binding for Alzheimer’s disease. We test our ligands with receptor/target binding and activation/inhibition assays, in vitro and in vivo electrophysiology, optogenetics and behavioural neuroscience.
Distinguished Award
  • Dr Gavin Stewart Dawe received his BSc (Hons) in Neuroscience from the University of Edinburgh, United Kingdom in 1990 and his PhD in Pharmacology from the Institute of Psychiatry, King’s College London, United Kingdom in 1995. After postdoctoral research at the Institute of Psychiatry, he worked with ReNeuron Limited and Eli Lilly and Company before joining the National University of Singapore (NUS). He is currently an Associate Professor, Deputy Head of Department and Education Director at the Department of Pharmacology, Yong Loo Lin School of Medicine, NUS.
  • At NUS he also serves as Core Leader of the Neuroscience Phenotyping Core; as a member of the NUS Graduate School for Integrative Sciences and Engineering; and as a Principal Investigator under the Neurobiology and Ageing Programme, Life Sciences Institute, and the Singapore Institute for Neurotechnology (SINAPSE). He is currently Vice President of the Singapore Neuroscience Association and of the Pharmacological Society (Singapore).

Venus International Foundation © 2015 | All rights reserved

Working hours: 10:00 A.M. - 4:30 P.M.| Page last updated on: Feb 13, 2018